"First-party" drug audit program to be proposed by FDA in upcoming Federal Register.
This article was originally published in The Tan Sheet
Executive Summary
"FIRST-PARTY" DRUG AUDIT PROGRAM TO BE PROPOSED BY FDA in an upcoming Federal Register notice, Center for Drug Evaluation & Research Compliance Office Director Stephanie Gray told the Pharm Tech annual conference in Philadelphia Sept. 15. The program, designed to help streamline FDA's enforcement of Good Manufacturing Practice regs for drugs, will allow companies with good quality control track records the option of submitting in-house audits to the agency in return for fewer inspections on more specific issues, Gray explained.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: